Sisk saw £110m fit out contract pulled following decision by US drug maker Merck
The developer behind a life sciences building in London that a US drugs maker changed its mind about moving into has said it is speaking to would-be occupiers as Mace prepares to finish up its shell and core contract later this spring.
The King’s Cross block, known as Belgrove House, had been due to be occupied by Merck but the US drug maker, which is known as MSD in Europe, said last autumn the UK was uncompetitive and paying too little for medicines – meaning it would not now move into it as planned.
Sisk had been lined up for a £110m contract to carry out fit out work at the site opposite King’s Cross station but the deal was pulled in the wake of Merck’s decision.
Mace’s contract was unaffected with the firm now close to completing the shell and core of the 10-storey block in a deal thought to be worth around £150m.
The building, designed by architect AHMM, is being developed by Precis Advisory and has been built on a former Access self-storage warehouse on the Euston Road.
In a statement, Precis said Mace was on track to complete its work this spring and added: ““Precis Advisory remain committed to providing world-class facilities that reflect the ambition and significance of the location.
“Situated in the heart of the Knowledge Quarter, Belgrove House offers exceptional connectivity, positioning it as a highly accessible and strategic central location. We are now working with agents and exploring options for potential occupiers.”
Precis has previously said laboratories make up around 40% of the building’s total floorspace with associated office, research and ‘write-up’ space at levels four to nine.
No comments yet